Hinge Health stock pops 6% after first quarterly report since IPO

Hinge Health stock pops 6% after first quarterly report since IPO


Hinge Health co-founders, Gabriel Mecklenburg and Daniel Perez celebrate its initial public offering at the New York Stock Exchange on May 22, 2025.

NYSE

Shares of Hinge Health popped 6% in extended trading on Tuesday after the digital physical therapy company reported quarterly results for the first time since its debut on the New York Stock Exchange in May.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Loss: Loss per share of $13.10. That may not compare with the 9 cents per share earnings expected
  • Revenue: $139 million vs. $125 million expected

Revenue at Hinge increased 55% in the second quarter from $89.8 million during the same period last year, according to a release.

Hinge reported a net loss of $575.65 million, or $13.10 per share, compared to a loss of $12.93 million, a loss of 96 cents per share, during the same period a year earlier. The company said its GAAP loss from operations was $580.7 million, which included $591.0 million from stock-based compensation expenses.

“We’re still introducing ourselves to the world,” Hinge CEO Daniel Perez told CNBC in an interview on Tuesday. “The most important thing I’d hope for people to take away is the long-term potential of using software and connected hardware to automate care delivery itself.”

Hinge, founded in 2014, uses software to help patients treat acute musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely.

It finished the second quarter with 2,359 clients, up 39% from 1,785 clients during the same period last year.

Hinge said it expects to report revenue between $141 million and $143 million during its third quarter. LSEG analysts were expecting $129 million. For the full year, the company said it expects revenue of $548 million to $552 million, which also beat the $511 million expected by LSEG analysts.

The stock opened at $39.25 in May, rising 23% from its $32 IPO price. Shares of Hinge closed at $48.22 on Tuesday.

“We believe we’re fundamentally reshaping how care can be delivered more effectively and efficiently,” Perez said during the company’s quarterly call with investors.

Stock Chart IconStock chart icon

hide content

Hinge Health 3 month stock chart.

I'd consider buying Hinge Health at these levels, says Jim Cramer



Source

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More
Candy giant Mars partners with biotech firm to gene-edit cocoa supply
Health

Candy giant Mars partners with biotech firm to gene-edit cocoa supply

Packages of M&M’s milk chocolate candy are stacked at a Costco Wholesale store on July 12, 2025 in San Diego, California. Kevin Carter | Getty Images News | Getty Images Candy maker Mars said Wednesday it’s partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology. […]

Read More
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
Health

Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For […]

Read More